We are live on
!
Find out more
Primecap Management Portfolio holdings
AUM
$127B
1-Year Est. Return
44.11%
This Fund
S&P 500
This Quarter
Est. Return
+8.41%
1 Year Est. Return
+44.11%
3 Year Est. Return
+121.64%
5 Year Est. Return
+154.22%
10 Year Est. Return
+724.54%
AUM
$110B
AUM Growth
+$8.55B
(+8.4%)
Cap. Flow
+$733M
Cap. Flow
% of AUM
0.67%
Top 10 Holdings %
Top 10 Hldgs %
32.31%
Holding
285
New
9
Increased
94
Reduced
125
Closed
3
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BIVV
Bioverativ Inc. Common Stock
BIVV
|
+$381M |
| 2 |
AstraZeneca
AZN
|
+$242M |
| 3 |
Citigroup
C
|
+$201M |
| 4 |
Bath & Body Works
BBWI
|
+$145M |
| 5 |
Hewlett Packard
HPE
|
+$125M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Intel
INTC
|
+$267M |
| 2 |
SCHW
Charles Schwab
SCHW
|
+$160M |
| 3 |
Amgen
AMGN
|
+$148M |
| 4 |
Johnson & Johnson
JNJ
|
+$146M |
| 5 |
Medtronic
MDT
|
+$131M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 30.65% |
| 2 | Healthcare | 23.76% |
| 3 | Industrials | 15.73% |
| 4 | Consumer Discretionary | 8.92% |
| 5 | Financials | 7.98% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
OMED
201
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
| $17.6M | 0.02% |
1,906,600
+105,900
| +6% | +$930K |
|
202
AutoZone
AZO
$47.7B
| $17.2M | 0.02% |
23,775
| – | – |
|
203
Mercury Insurance
MCY
$5.84B
| $17.2M | 0.02% |
281,600
| – | – |
|
204
Public Service Enterprise Group
PEG
$39.8B
| $16.5M | 0.02% |
372,379
| – | – |
|
|
MB
205
DELISTED
MINDBODY, Inc. Class A Common Stock
MB
| $16.4M | 0.01% |
598,877
| – | – |
|
206
OraSure Technologies
OSUR
$277M
| $16.3M | 0.01% |
1,261,500
-500
| -0% | -$5.17K |
|
|
IMGN
207
DELISTED
Immunogen Inc
IMGN
| $15.3M | 0.01% |
3,966,000
-1,086,943
| -22% | -$3.17M |
|
208
Avis
CAR
$5.62B
| $15.1M | 0.01% |
510,100
| – | – |
|
|
PFNX
209
DELISTED
Pfenex Inc.
PFNX
| $13.8M | 0.01% |
2,368,100
| – | – |
|
210
Magnite
MGNI
$2.57B
| $13.4M | 0.01% |
2,282,800
-632,528
| -22% | -$4.93M |
|
211
Arbutus Biopharma
ABUS
$883M
| $12.8M | 0.01% |
3,940,400
+5,400
| +0.1% | +$15K |
|
|
BUFF
212
DELISTED
Blue Buffalo Pet Products, Inc
BUFF
| $12.6M | 0.01% |
548,200
-78,800
| -13% | -$1.94M |
|
213
Digimarc Corp
DMRC
$132M
| $12.4M | 0.01% |
460,000
+107,000
| +30% | +$2.8M |
|
214
Ciena
CIEN
$57.7B
| $12.1M | 0.01% |
512,641
-4,829
| -0.9% | -$118K |
|
215
MaxLinear
MXL
$8.17B
| $12M | 0.01% |
428,700
+140,000
| +48% | +$3.59M |
|
|
CNR
216
DELISTED
Cornerstone Building Brands, Inc.
CNR
| $11.7M | 0.01% |
680,000
+10,000
| +1% | +$161K |
|
|
POT
217
DELISTED
Potash Corp Of Saskatchewan
POT
| $10.9M | 0.01% |
640,000
-104,700
| -14% | -$1.9M |
|
218
Expeditors International
EXPD
$23B
| $10.8M | 0.01% |
190,300
-339,100
| -64% | -$18.6M |
|
|
TUES
219
DELISTED
Tuesday Morning Corp
TUES
| $10.2M | 0.01% |
2,729,524
-83,376
| -3% | -$339K |
|
|
AXON
220
Axon Enterprise
AXON
$39.6B
| $10.2M | 0.01% |
447,000
+77,000
| +21% | +$1.89M |
|
|
SPLK
221
DELISTED
Splunk Inc
SPLK
| $9.97M | 0.01% |
160,000
+100,300
| +168% | +$6M |
|
|
ESL
222
DELISTED
Esterline Technologies
ESL
| $9.75M | 0.01% |
113,331
| – | – |
|
223
Signet Jewelers
SIG
$3.48B
| $9.47M | 0.01% |
136,700
| – | – |
|
224
Constellium
CSTM
$4.08B
| $9.4M | 0.01% |
1,445,700
-106,700
| -7% | -$762K |
|
|
TVIA
225
DELISTED
TerraVia Holdings, Inc. Common Stock
TVIA
| $9.18M | 0.01% |
12,671,746
+62,825
| +0.5% | +$58.5K |
|
Similar funds
Primecap Management's Q1 2017 Portfolio in Review
As of Q1 2017, Primecap Management held 285 positions worth $110B, up 8.4% from $102B the previous quarter. Its ten largest holdings account for 32% of the portfolio.
Trading was light in Q1 2017: portfolio turnover was 4.2%. Primecap Management opened 9 new positions and exited 3, leaving the 285-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 31% of assets, up from 30% a quarter earlier, followed by Healthcare and Industrials.
- Primecap Management's largest Q1 2017 buy was Bioverativ Inc. Common Stock: 7,741,094 shares worth $422M.
- Primecap Management added most to AstraZeneca in Q1 2017, an estimated $242M increase.
- Primecap Management's biggest Q1 2017 reduction was Intel, cutting an estimated $267M.
- Primecap Management fully exited C.H. Robinson in Q1 2017, selling an estimated $14.4M.
- Primecap Management's ten largest holdings make up 32% of its $110B portfolio in Q1 2017.
- Primecap Management opened 9 new positions and closed 3 in Q1 2017.
- Primecap Management's portfolio value rose 8.4% quarter-over-quarter to $110B.
Based on Primecap Management's 13F filing for Q1 2017, filed 12 May 2017.